Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 11:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: single dose (100 mg) of ASA Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants

NCT07652723
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
Aspirin, BAY3389934
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin

NCT04328883
View directory record Official record
Conditions
Platelet Aggregation Inhibitors
Interventions
Aspirin
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 26, 2026, 11:55 PM EDT
Terminated Phase 4 Interventional Results available

PROUD Study - Preventing Opioid Use Disorders

NCT04766996
View directory record Official record
Conditions
Anesthesia, Opioid Use
Interventions
Guided mindfulness exercises, Self-administered aromatherapy, Baby aspirin, Tylenol/Acetaminophen, Pregabalin, Prednisone, Meloxicam, Prilosec, Tramadol, Voltaren, Zofran, Pepcid, Reglan, Versed, Lidocaine, Propofol, Ancef, Tranexamic Acid (TXA), Decadron, Bupivacaine hydrochloride, Toradol
Behavioral · Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 26, 2026, 11:55 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

NCT00984113
View directory record Official record
Conditions
Renal Impairment
Interventions
Elinogrel
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 26, 2026, 11:55 PM EDT
Active, not recruiting Not applicable Interventional

SIMPLAAFY Clinical Trial

NCT06521463
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
WATCHMAN FLX Pro LAAC Device
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

NCT00833833
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Dexamethasone, Aspirin
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
14
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

NCT03844191
View directory record Official record
Conditions
Coronary Disease
Interventions
RUC-4 Compound
Drug
Lead sponsor
CeleCor Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine

NCT01248468
View directory record Official record
Conditions
Pain, Migraine
Interventions
Aspirin, acetaminophen and caffeine, Sumatriptan, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Anaheim, California • San Francisco, California • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 26, 2026, 11:55 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 26, 2026, 11:55 PM EDT
Recruiting Phase 4 Interventional

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

NCT06655376
View directory record Official record
Conditions
Bleeding, Clot Blood
Interventions
Aspirin, Warfarin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.

NCT05625334
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASA, non-enteric-coated chewable aspirin
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder

NCT00345605
View directory record Official record
Conditions
Argininosuccinic Aciduria, Amino Acid Metabolism, Inborn Errors, Urea Cycle Disorders
Interventions
Sodium Phenylbutyrate, Arginine
Drug
Lead sponsor
Brendan Lee
Other
Eligibility
5 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 26, 2026, 11:55 PM EDT
Terminated Phase 1 Interventional

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

NCT05625347
View directory record Official record
Conditions
Obstructive Pulmonary Function, Restrictive Pulmonary Function
Interventions
single dose (100 mg) of ASA, single dose (162 mg) of non-enteric-coated chewable aspirin tablets
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 26, 2026, 11:55 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

NCT03805932
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience, Dexamethasone, Acetaminophen, Diphenhydramine, Famotidine, Aspirin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 26, 2026, 11:55 PM EDT